Stoke Therapeutics (NASDAQ:STOK) Insider Barry Ticho Sells 5,545 Shares

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 5,545 shares of the company’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $30.67, for a total value of $170,065.15. Following the transaction, the insider directly owned 20,110 shares in the company, valued at $616,773.70. This represents a 21.61% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Barry Ticho also recently made the following trade(s):

• On Tuesday, August 18th, Barry Ticho sold 4,767 shares of Stoke Therapeutics stock. The stock was sold at an average price of $32.03, for a total value of $152,687.01.
• On Monday, August 3rd, Barry Ticho sold 7,176 shares of Stoke Therapeutics stock. The shares were sold at an average price of $29.04, for a total transaction of $208,391.04.

Stoke Therapeutics Stock Down 1.7%

Shares of NASDAQ:STOK opened at $29.99 on Friday. The firm has a market capitalization of $1.94 billion, a PE ratio of -8.98 and a beta of 1.23. The company has a 50-day moving average price of $31.22 and a two-hundred day moving average price of $32.22. Stoke Therapeutics, Inc. has a twelve month low of $18.80 and a twelve month high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.13). The business had revenue of $9.32 million during the quarter, compared to the consensus estimate of $4.89 million. Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. Analysts anticipate that Stoke Therapeutics, Inc. will post -3.52 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Stoke Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Kestra Advisory Services LLC bought a new position in Stoke Therapeutics in the 4th quarter worth about $26,000. Quantbot Technologies LP bought a new stake in shares of Stoke Therapeutics during the 2nd quarter valued at about $34,000. KBC Group NV bought a new stake in shares of Stoke Therapeutics during the 1st quarter valued at about $36,000. Harbour Investments Inc. grew its holdings in shares of Stoke Therapeutics by 312.9% during the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock worth $38,000 after purchasing an additional 898 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in shares of Stoke Therapeutics by 66.2% during the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after purchasing an additional 1,668 shares in the last quarter.

Analyst Ratings Changes

A number of brokerages recently issued reports on STOK. Guggenheim reissued a “buy” rating and set a $60.00 price objective on shares of Stoke Therapeutics in a report on Tuesday, August 4th. Wedbush lifted their target price on Stoke Therapeutics from $38.00 to $40.00 and gave the company an “outperform” rating in a report on Tuesday, August 4th. Chardan Capital reiterated a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a research report on Tuesday, August 4th. BTIG Research reissued a “buy” rating and issued a $39.00 price target on shares of Stoke Therapeutics in a report on Monday, May 11th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Stoke Therapeutics in a research report on Friday, August 21st. They issued an “overweight” rating and a $40.00 price objective for the company. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Stoke Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $44.25.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.